Ubrelvy 50 mg (Ubrogepant TABLET) 50 MG

Ubrelvy 50 mg is a CGRP receptor antagonist used to treat migraine headaches. It is specifically indicated for the acute treatment of migraine with or without aura.

• Migraine with aura: Provides relief from migraine attacks that are preceded by sensory disturbances such as visual disturbances, numbness, or speech difficulties.
• Migraine without aura: Offers relief from migraine attacks that occur without preceding sensory disturbances.
• Acute migraine treatment: Helps to alleviate the pain and other symptoms associated with migraine attacks.

• Ubrelvy 50 mg works by selectively antagonizing the calcitonin gene-related peptide (CGRP) receptor. By inhibiting CGRP-mediated vasodilation and nociceptive signaling, it helps to reduce the pain and other symptoms associated with migraine attacks. This mechanism targets the underlying pathways involved in migraine pathophysiology.

Ubrelvy 50 mg may cause various side effects, ranging from common to serious or rare.

Common Side Effects

• Dry mouth: A frequent side effect that may occur during treatment.
• Nausea: Some patients may experience feelings of nausea.
• Sleepiness: Drowsiness or reduced alertness may be experienced.
• Fatigue: A general feeling of tiredness or lack of energy.
• Dizziness: Some patients may feel lightheaded or dizzy.
• Constipation: Difficulty in passing stools may occur.
• Vomiting: Some patients may experience vomiting.
• Abdominal pain: Discomfort or pain in the abdominal area.

Serious or Rare Side Effects

• Allergic reactions: Signs of a serious allergic reaction include abdominal cramps, difficulty breathing, nausea and vomiting, or swelling of the face and throat. Immediate medical attention is required if these symptoms occur.

Ubrelvy 50 mg should be used with caution and under the supervision of a healthcare professional. Important precautions include:

• Liver function: Liver disease or reduced liver function may cause the medication to build up in the body, leading to increased side effects. Regular monitoring of liver function is recommended.
• Pregnancy: This medication should not be used during pregnancy unless the benefits outweigh the risks. Consult your doctor if you are pregnant or planning to become pregnant.
• Birth control: Ubrogepant may decrease the effectiveness of hormonal birth control. A second method of birth control should be used.
• Grapefruit or grapefruit juice: Avoid consuming grapefruit or grapefruit juice as it may increase the levels of ubrogepant in the body, leading to an increase in side effects.
• Driving or operating machinery: Ubrogepant may cause sleepiness, affecting your ability to drive or operate machinery. Avoid these activities until you know how the medication affects you.
• Store below 25°C: Keep in the original pack, protect from moisture.

Ubrelvy 50 mg may interact with other medications, leading to potential complications. It is important to inform your healthcare provider about all the medications you are taking.

Major Interactions (Avoid)

• Telotristat: Avoid concomitant use as it may increase the risk of side effects.
• Teriflunomide: Avoid concomitant use as it may increase the risk of side effects.
• Tocilizumab: Avoid concomitant use as it may increase the risk of side effects.
• Upadacitinib: Avoid concomitant use as it may increase the risk of side effects.
• Verapamil: Avoid concomitant use as it may increase the risk of side effects.

Moderate Interactions (Monitor Closely)

• Hormonal birth control: Ubrogepant may decrease the effectiveness of hormonal birth control. A second method of birth control should be used.
• Grapefruit or grapefruit juice: Avoid consuming grapefruit or grapefruit juice as it may increase the levels of ubrogepant in the body, leading to an increase in side effects.